2008 Clinical Practice Guidelines - Canadian Diabetes Association

of diabetes mellitus in patients with myocardial infarction and
effect of diabetes on survival. The Minnesota Heart Survey.
Diabetes Care. 1991;14:537-543.
10. Fuller JH, Stevens LK,Wang SL. Risk factors for cardiovascular
mortality and morbidity: the WHO Mutinational Study of
Vascular Disease in Diabetes. Diabetologia. 2001;44(suppl 2):
S54-S64.
11. Malmberg K, Ryden L, Hamsten A, et al. Mortality prediction
in diabetic patients with myocardial infarction: experiences
from the DIGAMI study. Cardiovasc Res. 1997;34:248-253.
12. Stevens RJ, Coleman RL, Adler AI, et al. Risk factors for
myocardial infarction case fatality and stroke case fatality in
type 2 diabetes: UKPDS 66. Diabetes Care. 2004;27:201-207.
13. Antman EM,Anbe DT,Armstrong PW, et al.ACC/AHA guidelines
for the management of patients with ST elevation myocardial
infarction — executive summary: a report of the American
College of Cardiology/American Heart Association Task Force
on Practice Guidelines (Writing Committee to Revise the 1999
Guidelines for the Management of Patients with Acute
Myocardial Infarction). Circulation. 2004;110:588-636.
14. Braunwald E,Antman EM, Beasley JW, et al.ACC/AHA 2002
guideline update for the management of patients with unstable
angina and non-ST-segment elevation myocardial infarction—
summary article: a report of the American College of
Cardiology/American Heart Association task force on practice
guidelines (Committee on the Management of Patients with
Unstable Angina). J Am Coll Cardiol. 2002;40:1366-1374.
15. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA
guidelines for the management of patients with unstable angina
and non-ST-segment elevation myocardial infarction. A
report of the American College of Cardiology/American
Heart Association Task Force on Practice Guidelines
(Committee on the Management of Patients with Unstable
Angina). J Am Coll Cardiol. 2000;36:970-1062.
16. Bertrand ME, Simmoons ML, Fox KA, et al. Management of
acute coronary syndromes: acute coronary syndromes without
persistent ST segment elevation. Recommendations of the Task
Force of the European Society of Cardiology. Eur Heart J. 2000;
21:1406-1432.
17. Fibrinolytic Therapy Trialists (FTT) Collaborative Group.
Indications for fibrinolytic therapy in suspected acute myocardial
infarction: collaborative overview of early mortality and
major morbidity results from all randomized trials of more
than 1000 patients. Lancet. 1994;343:311-322.
18. Grines C, Patel A, Zijlstra F, et al; PCAT Collaborators.
Percutaneous transluminal coronary angioplasty. Primary
coronary angioplasty compared with intravenous thrombolytic
therapy for acute myocardial infarction: six-month follow up
and analysis of individual patient data from randomized trials.
Am Heart J. 2003;145:47-57.
19. Bonnefoy E, Steg PG, Chabaud S, et al. Is primary angioplasty
more effective than prehospital fibrinolysis in diabetics with
acute myocardial infarction? Data from the CAPTIM randomized
clinical trial. Eur Heart J. 2005;26:1712-1718.
20. Cannon CP, Weintraub WS, Demopoulos LA et al; TACTICS
(Treat Angina with Aggrastat and Determine Cost of Therapy
with an Invasive or Conservative Strategy) — Thrombolysis in
Myocardial Infarction 18 Invest. Comparison of early invasive
and conservative strategies in patients with unstable coronary
syndromes treated with the glycoprotein IIb/IIIa inhibitor
tirofiban. N Engl J Med. 2001;344:1879-1887.
21. Yusuf S, Zhao F, Mehta SR, et al; Clopidogrel in Unstable
Angina to Prevent recurrent Events Trial Investigators. Effects
of clopidogrel in addition to aspirin in patients with acute
coronary syndromes without ST-segment elevation. N Engl J
Med. 2001;345:494-502.
22. Roffi M, Chew DP, Mukherjee D, et al. Platelet glycoprotein
IIb/IIIa inhibitors reduce mortality in diabetic patients with
non-ST-segment-elevation acute coronary syndromes.
Circulation. 2001;104:2767-2771.
23. Mahaffey KW, Granger CB,Toth CA, et al. Diabetic retinopathy
should not be a contraindication to thrombolytic therapy
for acute myocardial infarction: a review of ocular hemorrhage
incidence and location in the GUSTO-I trial. Global
Utilization of Streptokinase and t-PA for Occluded Coronary
Arteries. J Am Coll Cardiol. 1997;30:1606-1610.
24. Ishihara M, Kojima S, Sakamoto T, et al. Acute hyperglycemia
is associated with adverse outcome after acute myocardial
infarction in the coronary intervention era. Am Heart J. 2005;
150:814-820.
25. Hadjadj S, Coisne D, Mauco G, et al. Prognostic value of
admission plasma glucose and HbA in acute myocardial infarction.
Diabet Med. 2004;21:305-310.
26. Ainla T, Baburin A, Teesalu R, et al. The association between
hyperglycaemia on admission and 180-day mortality in acute
myocardial infarction patients with and without diabetes.
Diabet Med. 2005;22:1321-1325.
27. Almbrand B, Johannesson M, Sjostrand B, et al. Cost-effectiveness
of intense insulin treatment after acute myocardial
infarction in patients with diabetes mellitus; results from the
DIGAMI study. Eur Heart J. 2000;21:733-739.
28. Davies MJ, Lawrence IG. DIGAMI (Diabetes Mellitus, Insulin
Glucose Infusion in Acute Myocardial Infarction): theory and
practice. Diabetes Obes Metab. 2002;4:289-295.
29. Malmberg K. Prospective randomised study of intensive insulin
treatment on long term survival after acute myocardial infarction
in patients with diabetes mellitus. DIGAMI (Diabetes
Mellitus, Insulin Glucose Infusion in Acute Myocardial
Infarction) Study Group. BMJ. 1997;314:1512-1515.
30. Malmberg K, Ryden L, Hamsten A, et al. Effects of insulin
treatment on cause-specific one-year mortality and morbidity
in diabetic patients with acute myocardial infarction. DIGAMI
Study Group. Diabetes Insulin-Glucose in Acute Myocardial
Infarction. Eur Heart J. 1996;17:1337-1344.
31. Malmberg KA, Efendic S, Ryden LE. Feasibility of insulin-glucose
infusion in diabetic patients with acute myocardial infarction.
A report from the multicenter trial: DIGAMI. Diabetes
Care. 1994;17:1007-1014.
S121
COMPLICATIONS AND COMORBIDITIES